DK0565377T3 - Terapeutiske midler til behandling af Parkinsons sygdom - Google Patents

Terapeutiske midler til behandling af Parkinsons sygdom

Info

Publication number
DK0565377T3
DK0565377T3 DK93302780.7T DK93302780T DK0565377T3 DK 0565377 T3 DK0565377 T3 DK 0565377T3 DK 93302780 T DK93302780 T DK 93302780T DK 0565377 T3 DK0565377 T3 DK 0565377T3
Authority
DK
Denmark
Prior art keywords
group
parkinson
disease
treatment
therapeutic agents
Prior art date
Application number
DK93302780.7T
Other languages
Danish (da)
English (en)
Inventor
Akio Ishii
Fumio Suzuki
Shunji Ichikawa
Junichi Shimada
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of DK0565377T3 publication Critical patent/DK0565377T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK93302780.7T 1992-04-08 1993-04-08 Terapeutiske midler til behandling af Parkinsons sygdom DK0565377T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8711592 1992-04-08

Publications (1)

Publication Number Publication Date
DK0565377T3 true DK0565377T3 (da) 1998-03-16

Family

ID=13905960

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93302780.7T DK0565377T3 (da) 1992-04-08 1993-04-08 Terapeutiske midler til behandling af Parkinsons sygdom

Country Status (11)

Country Link
EP (1) EP0565377B1 (de)
JP (1) JP2613352B2 (de)
AT (1) ATE161723T1 (de)
BR (1) BR1100636A (de)
CA (1) CA2093403C (de)
DE (1) DE69316067T2 (de)
DK (1) DK0565377T3 (de)
ES (1) ES2112386T3 (de)
GR (1) GR3026233T3 (de)
HK (1) HK1001835A1 (de)
NO (1) NO303265B1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2106771C (en) * 1992-02-19 2004-11-02 Yukio Ishida Highly water absorbed rice, method for producing same and application of same
US5543415A (en) * 1992-07-08 1996-08-06 Kyowa Hakko Kogyo Co., Ltd. Antidepressants
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
AU6781194A (en) * 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
ZA945609B (en) * 1993-07-28 1995-05-12 Rhone Poulenc Rorer Ltd [Di(ether or thioether)heteroaryl or fluoro substituted aryl] compounds
CA2161011A1 (en) * 1994-02-23 1995-08-31 Fumio Suzuki Xanthine derivatives
ATE281835T1 (de) * 1996-08-07 2004-11-15 Kyowa Hakko Kogyo Kk Fettemulsion, die ein xanthinderivat enthält
DE69834500T2 (de) * 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
EP1440072A4 (de) 2001-10-30 2005-02-02 Conforma Therapeutic Corp Purinanaloga mit hsp90-inhibierender wirkung
MXPA05011371A (es) 2003-04-25 2005-12-01 Novacardia Inc Metodo para mejorar la diuresis en individuos con la funcion renal deteriorada.
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
ES2532479T3 (es) 2004-01-28 2015-03-27 Kyowa Hakko Kirin Co., Ltd. Agentes para el tratamiento de la migraña
KR20080004550A (ko) * 2005-03-30 2008-01-09 콘포마 세러퓨틱스 코포레이션 Ｈｓｐ９０-억제제로서 알키닐 피롤로피리미딘 및 관련유사체
CA2608111A1 (en) * 2005-04-22 2006-11-02 Novacardia, Inc. Production of emulsions for intravenous injection of water-insoluble pharmaceutical compositions
KR20090094465A (ko) * 2006-12-22 2009-09-07 슈바르츠 파르마 악티엔게젤샤프트 선택적 ａ2ａ 수용체 안타고니스토로서의 8-알키닐잔틴 유도체
US7994357B2 (en) * 2009-04-03 2011-08-09 Naturewise Biotech & Medicals Corporation Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
WO2020125779A1 (en) * 2018-12-21 2020-06-25 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
US20220202822A1 (en) * 2019-04-24 2022-06-30 Sunshine Lake Pharma Co., Ltd. 8-substituted aryl vinyl xanthine derivatives and uses thereof
CN110041331B (zh) * 2019-05-17 2020-08-07 广东东阳光药业有限公司 苯乙烯基黄嘌呤衍生物及其用途
CN112409360B (zh) * 2019-08-22 2022-12-23 广东东阳光药业有限公司 杂芳基乙烯基黄嘌呤衍生物及其用途
US20230017597A1 (en) * 2019-11-11 2023-01-19 Sunshine Lake Pharma Co., Ltd. 8-substituted styryl xanthine derivatives and uses thereof
CN111072663B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途
CN111018856B (zh) * 2019-12-12 2021-10-01 广东东阳光药业有限公司 8-取代的苯乙烯基黄嘌呤衍生物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH512486A (fr) * 1969-07-30 1971-09-15 Parke Davis & Co Procédé de préparation de xanthines
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
ES2130138T3 (es) * 1990-10-18 1999-07-01 Kyowa Hakko Kogyo Kk Derivado de xantina.

Also Published As

Publication number Publication date
ES2112386T3 (es) 1998-04-01
BR1100636A (pt) 2000-04-18
DE69316067T2 (de) 1998-07-02
NO303265B1 (no) 1998-06-22
ATE161723T1 (de) 1998-01-15
NO931317L (no) 1993-10-11
NO931317D0 (no) 1993-04-06
GR3026233T3 (en) 1998-05-29
JP2613352B2 (ja) 1997-05-28
CA2093403A1 (en) 1993-10-09
EP0565377B1 (de) 1998-01-07
CA2093403C (en) 1999-08-10
DE69316067D1 (de) 1998-02-12
HK1001835A1 (en) 1998-07-10
EP0565377A1 (de) 1993-10-13
JPH0616559A (ja) 1994-01-25

Similar Documents

Publication Publication Date Title
DK0565377T3 (da) Terapeutiske midler til behandling af Parkinsons sygdom
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
DE69418704D1 (de) Anthranilsäure derivate
DE69130120D1 (de) Derivate von zyklischen Amiden
DE69331843D1 (de) Xanthine-Derivate als Antidepressiva
DE69221794D1 (de) 3-benzyliden-1-carbamoyl-2-pyrrolidon-analoga
HUT68856A (en) Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions
ATE34976T1 (de) Arylcyclobutylalkylamine und ihre verwendung als antidepressive arzneimittel.
KR910009672A (ko) 피리다진 유도체, 이의 제조방법 및 이것을 함유하는 약학 조성물
FI884088A0 (fi) Foerfarande foer framstaellning av 17-substituerade androsta-1,4-dien-3-onderivat.
FI941958A0 (fi) 2-heterosyklinenetyyliamiinijohdannaiset ja niiden käyttö lääkkeinä
DE69110217D1 (de) Derivate der Kaffeinsäure und sie enthaltende pharmazeutische Zusammensetzungen.
DE69626624D1 (de) Medikamente gegen trhombocytopenie
DK0461012T3 (da) Derivater af ((1-arylpyrrolidin-2-yl)methyl)piperazin, fremstillingen heraf og deres terapeutiske anvendelse
FR2694557B1 (fr) Dérivés de tétrahydronaphtalène, leur préparation, et leur application en thérapeutique.